Step 1 topics → Psychiatry → Valproate as Mood Stabilizer

Valproate as Mood Stabilizer

USMLE Step 1 trap: Confuses valproate's neural tube teratogenicity with lithium's cardiac teratogenicity. Valproate causes neural tube defects (spina bifida) by inhibiting folate metabolism, not cardiac malformations.

Valproate (valproic acid, Depakote) wears multiple hats: it's an anticonvulsant, a mood stabilizer, and a migraine prophylactic. USMLE Step 1 tests it from two main angles — its indications (including where it beats lithium) and its toxicity profile (which has some genuinely dangerous entries). Students who only know 'it treats bipolar' will miss the specificity the exam demands. You need to know when valproate is preferred over lithium, and you need to know its organ toxicities cold.

The trickiest part is that valproate and lithium are both mood stabilizers, so students collapse them into one mental category. That's a mistake. Valproate has a specific niche: mixed episodes, rapid cycling bipolar, and bipolar with comorbid seizures or migraines. Lithium is preferred for classic mania and has better evidence for suicide prevention. Step 1 will present a vignette with a patient whose features point specifically to valproate — don't default to lithium.

On the toxicity side, there are two high-yield traps. First, students confuse valproate's teratogenicity with lithium's. Lithium causes Ebstein anomaly (cardiac); valproate causes neural tube defects (spina bifida) by interfering with folate metabolism. Second, students underestimate valproate's serious organ toxicities — fatal hepatotoxicity (especially in children under 2 on polytherapy) and pancreatitis are tested and often missed. USMLE Step 1 rewards students who know these distinctions precisely.

From real student decks
32%have cards covering this topic
19%have mature cards

A gap in most decks — fewer than half of students in our cohort have cards covering this topic.

Common misconceptions

Common mistake
Wrong: Valproate's teratogenic risk is cardiac (like lithium's Ebstein anomaly).
Right: Valproate causes neural tube defects (spina bifida) by inhibiting folate metabolism, not cardiac malformations.
Lithium is the drug associated with Ebstein anomaly (downward displacement of the tricuspid valve — a cardiac defect). Valproate's teratogenic risk is entirely different: it inhibits folate metabolism, which is required for neural tube closure, causing defects like spina bifida. These are two separate drugs with two separate teratogenic mechanisms, and the exam will explicitly try to swap them. Lock in the pairing: valproate → neural tube defects; lithium → Ebstein anomaly.
Common mistake
Gap: Missing knowledge of valproate's hepatotoxicity and pancreatitis as serious organ toxicities
Valproate causes dose-independent fatal hepatotoxicity (especially in children under 2 on polytherapy) and pancreatitis, in addition to thrombocytopenia and weight gain.
Most students know valproate causes tremor and weight gain, but the dangerous toxicities are hepatotoxicity and pancreatitis. The hepatotoxicity is idiosyncratic (not dose-dependent), can be fatal, and is most common in children under 2 years old receiving polypharmacy — a classic high-yield detail. Pancreatitis is a separate, serious complication. If a Step 1 vignette shows elevated LFTs or lipase in a patient on valproate, you should immediately recognize these as known toxicities, not incidental findings.
Common mistake
Wrong: Valproate and lithium have identical indications in bipolar disorder.
Right: Valproate is preferred over lithium for mixed episodes, rapid cycling bipolar disorder, and bipolar disorder with comorbid seizures or migraines.
Lithium and valproate are both mood stabilizers, but they are not interchangeable. Lithium is the classic agent for euphoric mania and has the most evidence for long-term maintenance and suicide prevention. Valproate is preferred when the patient has mixed features (simultaneous depressive and manic symptoms), rapid cycling (≥4 episodes/year), or a comorbidity like epilepsy or migraines that valproate already treats. When the exam gives you a bipolar patient with any of these features, that's a signal pointing toward valproate, not lithium.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know both the psychiatric indications (bipolar disorder, especially mixed episodes and rapid cycling) and the non-psychiatric indications (epilepsy and migraine prophylaxis) for valproate.
  2. Recognize which clinical scenario calls for valproate over lithium — specifically patients with mixed features, rapid cycling, or comorbid seizure disorders or migraines.
  3. Identify valproate's teratogenic risk as neural tube defects (spina bifida), not cardiac anomalies — and understand the mechanism is inhibition of folate metabolism.
  4. Know valproate's serious organ toxicities: fatal idiosyncratic hepatotoxicity (especially in children under 2 on polytherapy), pancreatitis, and thrombocytopenia, in addition to common side effects like weight gain and tremor.

Can you avoid these mistakes?

A 28-year-old woman with bipolar disorder has had 5 mood episodes in the past year alternating between mania and depression. She also has migraines. Which mood stabilizer is most appropriate, and why?
A pregnant patient on valproate for bipolar disorder is concerned about birth defects. You tell her the primary teratogenic risk is which condition, and that the mechanism involves which metabolic pathway?
A 19-month-old child with epilepsy is being treated with multiple antiepileptic drugs including valproate. His parents bring him in for jaundice and lethargy. What valproate toxicity must you consider, and what population characteristic makes this child particularly high-risk?
A Step 1 vignette shows a patient with bipolar disorder who also has a seizure disorder. The question asks which medication would address both conditions. Walk through why valproate is the answer and what other indications make it unique among mood stabilizers.

Related topics

Bipolar I Disorder Major Depressive Disorder (MDD) Persistent Depressive Disorder (Dysthymia) Bipolar II Disorder

See how your Anki deck covers this topic.

Upload your deck for a free audit →